Harrow Health, Inc. (HROW) Stock Grade

About Harrow Health, Inc.'s fundamentals

Harrow Health is a specialty and generic drug manufacturer with a market capitalization of $1.8 billion that has demonstrated strong top-line momentum, with revenue growing 36.4% year-over-year. However, the company reported a net loss in its latest annual statement, resulting in a negative net margin of -1.9%, though it is generating positive free cash flow despite these accounting losses. The company does not pay a dividend and lacks sufficient profitability metrics to calculate traditional valuation ratios like P/E ratio and return on equity.